PAFAH1B3 and cancer: Recent studies showed PAFAH1B3 as a key metabolic driver was correlated with poor prognosis, and PAFAH1B3 knockdown or pharmacological inhibition impaired cancer cell survival through enhancing tumor-suppressing signaling lipids (33, 34).